NasdaqGS:TSHABiotechs
Taysha Gene Therapies (TSHA) Could Be 49% Below Fair Value After Russell Index Drop
Taysha Gene Therapies (TSHA) was recently removed from several Russell indexes, including the Russell 3000E and Russell Microcap families, a change that can influence trading flows as passive funds rebalance.
See our latest analysis for Taysha Gene Therapies.
Despite the index removals, Taysha Gene Therapies’ recent share price performance has been strong, with a 30 day share price return of 22.57% and a 90 day share price return of 46.33%, while the 1 year total shareholder return sits at a...